Intarcia's speed bump at the FDA turns into a roadblock, as regulators once again turn thumbs down on diabetes drug/device

Back in the fall of 2017, Intarcia CEO Kurt Graves handled the FDA’s rejection of its hotly promoted drug/device as something of a speed bump.

The problem was in the manufacturing of ITCA 650, the company noted, and they had a straight shot at getting it fixed and back up in front of the FDA as they barreled on to certain blockbuster status.